Signal transduction pathways provide opportunities to enhance HDL and apoAI-dependent reverse cholesterol transport

Current Pharmaceutical Biotechnology

Volumn 13, Issue 2, 2012, Pages 352-364

  Mulay, Vishwaroop ^a   Wood, Peta ^a   Rentero, Carles ^b   Enrich, Carlos ^b   Grewal, Thomas ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ABCA1; Cholesterol efflux; HDL; MAPK; PKA; PKC; Signal transduction; SR BI

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ABC TRANSPORTER; APOLIPOPROTEIN A1; CALCINEURIN; CALCIUM ION; CALMODULIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DIACYLGLYCEROL; FATTY ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE 2; MESSENGER RNA; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C; RAC PROTEIN; RECEPTOR FOR ACTIVATED C KINASE 1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCAVENGER RECEPTOR BI; SILDENAFIL; TADALAFIL; TYROSINE;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; AUTOPHOSPHORYLATION; CARDIOVASCULAR DISEASE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CHOLESTEROL TRANSPORT; DESORPTION; DIFFUSION; DOWN REGULATION; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; EFFUSION; ENDOSOME; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY ACID BLOOD LEVEL; HUMAN; IMMUNOMODULATION; INTRACELLULAR SPACE; KIDNEY CELL; LIGAND BINDING; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; LYSOSOME; MACROPHAGE; MONOCYTE; NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SMOOTH MUSCLE FIBER; STEROIDOGENESIS; UPREGULATION; VASCULITIS;

ANIMALS; APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT; CHOLESTEROL; HUMANS; LIPOPROTEINS, HDL; SIGNAL TRANSDUCTION;

EID: 84856411164     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799095356     Document Type: Review

References (150)

1. Ikonen, E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev., 2006, 86(4), 1237-1261.
2. Rothblat, G.H.; Phillips, M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol., 2010, 21(3), 229-238.
3. Meurs, I.; Van Eck, M.; Van Berkel, T.J. High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr. Pharm. Des., 2010, 16(13), 1445-1467.
4. Ahras, M.; Naing, T.; McPherson, R. Scavenger receptor class B type I localizes to a late endosomal compartment. J. Lipid. Res., 2008, 49(7), 1569-1576.
5. Heeren, J.; Beisiegel, U.; Grewal, T. Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2006, 26(3), 442-448.
6. Boadu, E.; Francis, G.A. The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways. J. Mol. Med., 2006, 84(4), 266-275.
7. Schmitz, G.; Grandl, M. The molecular mechanisms of HDL and associated vesicular trafficking mechanisms to mediate cellular lipid homeostasis. Arterioscler. Thromb. Vasc. Biol., 2009, 29(11), 1718-1722.
8. Pagler, T.A.; Rhode, S.; Neuhofer, A.; Laggner, H.; Strobl, W.; Hinterndorfer, C.; Volf, I.; Pavelka, M.; Eckhardt, E.R.; van der Westhuyzen, D.R.; Schutz, G.J.; Stangl, H. SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J. Biol. Chem., 2006, 281(16), 11193-11204.
9. Acton, S.; Rigotti, A.; Landschulz, K.T.; Xu, S.; Hobbs, H.H.; Krieger, M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 1996, 271(5248), 518-520.
10. Ji, Y.; Jian, B.; Wang, N.; Sun, Y.; Moya, M.L.; Phillips, M.C.; Rothblat, G.H.; Swaney, J.B.; Tall, A.R. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem., 1997, 272(34), 20982-20985.
11. Wang, N.; Silver, D.L.; Costet, P.; Tall, A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem., 2000, 275(42), 33053-33058.
12. Francis, G.A.; Knopp, R.H.; Oram, J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J. Clin. Invest., 1995, 96(1), 78-87.
13. Rogler, G.; Trumbach, B.; Klima, B.; Lackner, K.J.; Schmitz, G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler. Thromb. Vasc. Biol., 1995, 15(5), 683-690.
14. Walter, M.; Gerdes, U.; Seedorf, U.; Assmann, G. The high density lipoprotein-and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem. Biophys. Res. Commun., 1994, 205(1), 850-856.
15. Yancey, P.G.; Bortnick, A.E.; Kellner-Weibel, G.; de la Llera-Moya, M.; Phillips, M.C.; Rothblat, G.H. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol., 2003, 23(5), 712-719.
16. Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res., 2006, 98(11), 1352-1364.
17. Grewal, T.; de Diego, I.; Kirchhoff, M.F.; Tebar, F.; Heeren, J.; Rinninger, F.; Enrich, C. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J. Biol. Chem., 2003, 278(19), 16478-16481.
18. Kiss, R.S.; Maric, J.; Marcel, Y.L. Lipid efflux in human and mouse macrophagic cells: evidence for differential regulation of phospholipid and cholesterol efflux. J. Lipid Res., 2005, 46(9), 1877-1887.
19. Saddar, S.; Mineo, C.; Shaul, P.W. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler. Thromb. Vasc. Biol., 2010, 30(2), 144-150.
20. von Eckardstein, A.; Rohrer, L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr. Opin. Lipidol., 2009, 20(3), 197-205.
21. Deeg, M.A.; Bowen, R.F.; Oram, J.F.; Bierman, E.L. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Arterioscler. Thromb. Vasc. Biol., 1997, 17(9), 1667-1674.
22. Mendez, A.J.; Oram, J.F.; Bierman, E.L. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J. Biol. Chem., 1991, 266(16), 10104-10111.
23. Li, Q.; Tsujita, M.; Yokoyama, S. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages. Biochemistry, 1997, 36(40), 12045-12052.
24. Haidar, B.; Denis, M.; Krimbou, L.; Marcil, M.; Genest, J. Jr. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J. Lipid Res., 2002, 43(12), 2087-2094.
25. See, R.H.; Caday-Malcolm, R.A.; Singaraja, R.R.; Zhou, S.; Silverston, A.; Huber, M.T.; Moran, J.; James, E.R.; Janoo, R.; Savill, J.M.; Rigot, V.; Zhang, L.H.; Wang, M.; Chimini, G.; Wellington, C.L.; Tafuri, S.R.; Hayden, M.R. Protein kinase A sitespecific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J. Biol. Chem., 2002, 277(44), 41835-41842.
26. Wang, P.Y.; Weng, J.; Anderson, R.G. OSBP is a cholesterolregulated scaffolding protein in control of ERK 1/2 activation. Science, 2005, 307(5714), 1472-1476.
27. Wu, Y.Q.; Handwerger, S. High density lipoproteins stimulate molecular weight 80K protein phosphorylation in human trophoblast cells: evidence for a protein kinase-C-dependent pathway in human placental lactogen release. Endocrinology, 1992, 131(6), 2935-2940.
28. Nazih, H.; Nazih-Sanderson, F.; Magret, V.; Caron, B.; Goudemand, J.; Fruchart, J.C.; Delbart, C. Protein kinase Cdependent desensitization of HDL3-activated phospholipase C in human platelets. Arterioscler. Thromb. Vasc. Biol., 1994, 14(8), 1321-1326.
29. Walter, M.; Reinecke, H.; Nofer, J.R.; Seedorf, U.; Assmann, G. HDL3 stimulates multiple signaling pathways in human skin fibroblasts. Arterioscler. Thromb. Vasc. Biol., 1995, 15(11), 1975-1986.
30. Drobnik, W.; Mollers, C.; Resink, T.; Schmitz, G. Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients. Arterioscler. Thromb. Vasc. Biol., 1995, 15(9), 1369-1377.
31. Nofer, J.R.; Fobker, M.; Hobbel, G.; Voss, R.; Wolinska, I.; Tepel, M.; Zidek, W.; Junker, R.; Seedorf, U.; von Eckardstein, A.; Assmann, G.; Walter, M. Activation of phosphatidylinositolspecific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry, 2000, 39(49), 15199-15207.
32. Grewal, T.; Evans, R.; Rentero, C.; Tebar, F.; Cubells, L.; de Diego, I.; Kirchhoff, M.F.; Hughes, W.E.; Heeren, J.; Rye, K.A.; Rinninger, F.; Daly, R.J.; Pol, A.; Enrich, C. Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene, 2005, 24(38), 5809-5820.
33. Haidar, B.; Mott, S.; Boucher, B.; Lee, C.Y.; Marcil, M.; Genest, J. Jr. Cellular cholesterol efflux is modulated by phospholipidderived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts. J. Lipid Res., 2001, 42(2), 249-257.
34. Walter, M.; Reinecke, H.; Gerdes, U.; Nofer, J.R.; Hobbel, G.; Seedorf, U.; Assmann, G. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. J. Clin. Invest., 1996, 98(10), 2315-2323.
35. Yamauchi, Y.; Hayashi, M.; Abe-Dohmae, S.; Yokoyama, S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J. Biol. Chem., 2003, 278(48), 47890-47897.
36. Wang, N.; Chen, W.; Linsel-Nitschke, P.; Martinez, L.O.; Agerholm-Larsen, B.; Silver, D.L.; Tall, A.R. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J. Clin. Invest., 2003, 111(1), 99-107.
37. Chen, W.; Wang, N.; Tall, A.R. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J. Biol. Chem., 2005, 280(32), 29277-29281.
38. Martinez, L.O.; Agerholm-Larsen, B.; Wang, N.; Chen, W.; Tall, A.R. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J. Biol. Chem., 2003, 278(39), 37368-37374.
39. Garver, W.S.; Hossain, G.S.; Winscott, M.M.; Heidenreich, R.A. The Npc1 mutation causes an altered expression of caveolin-1, annexin II and protein kinases and phosphorylation of caveolin-1 and annexin II in murine livers. Biochim. Biophys. Acta, 1999, 1453(2), 193-206.
40. Walter, M.; Chen, F.W.; Tamari, F.; Wang, R.; Ioannou, Y.A. Endosomal lipid accumulation in NPC1 leads to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment. Biol. Cell, 2009, 101(3), 141-152.
41. Frank, P.G.; Galbiati, F.; Volonte, D.; Razani, B.; Cohen, D.E.; Marcel, Y.L.; Lisanti, M.P. Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins. Am. J. Physiol. Cell Physiol., 2001, 280(5), C1204-1214.
42. Rentero, C.; Evans, R.; Wood, P.; Tebar, F.; Vila de Muga, S.; Cubells, L.; de Diego, I.; Hayes, T.E.; Hughes, W.E.; Pol, A.; Rye, K.A.; Enrich, C.; Grewal, T. Inhibition of H-Ras and MAPK is compensated by PKC-dependent pathways in annexin A6 expressing cells. Cell Signal., 2006, 18(7), 1006-1016.
43. Hanriot, D.; Bello, G.; Ropars, A.; Seguin-Devaux, C.; Poitevin, G.; Grosjean, S.; Latger-Cannard, V.; Devaux, Y.; Zannad, F.; Regnault, V.; Lacolley, P.; Mertes, P.M.; Hess, K.; Longrois, D. Creactive protein induces pro-and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb. Haemost, 2008, 99(3), 558-569.
44. Chinetti-Gbaguidi, G.; Staels, B. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochim. Biophys. Acta, 2009, 1791(6), 486-493.
45. Delvecchio, C.J.; Capone, J.P. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol., 2008, 197(1), 121-130.
46. Shetty, S.; Eckhardt, E.R.; Post, S.R.; van der Westhuyzen, D.R. Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes. Arterioscler. Thromb. Vasc. Biol., 2006, 26(9), 2125-2131.
47. Mackay, H.J.; Twelves, C.J. Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer, 2007, 7(7), 554-562.
48. Wang, Y.; Oram, J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J. Lipid Res., 2007, 48(5), 1062-1068.
49. Bright, R.; Mochly-Rosen, D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke, 2005, 36(12), 2781-2790.
50. Inagaki, K.; Mochly-Rosen, D. DeltaPKC-mediated activation of epsilonPKC in ethanol-induced cardiac protection from ischemia. J. Mol. Cell. Cardiol., 2005, 39(2), 203-211.
51. Rosse, C.; Linch, M.; Kermorgant, S.; Cameron, A.J.; Boeckeler, K.; Parker, P.J. PKC and the control of localized signal dynamics. Nat. Rev. Mol. Cell Biol., 2010, 11(2), 103-112.
52. Steinberg, S.F. Structural basis of protein kinase C isoform function. Physiol. Rev., 2008, 88(4), 1341-1378.
53. Kheifets, V.; Mochly-Rosen, D. Insight into intra-and intermolecular interactions of PKC: design of specific modulators of kinase function. Pharmacol. Res., 2007, 55(6), 467-476.
54. Grewal, T.; Koese, M.; Rentero, C.; Enrich, C. Annexin A6-regulator of the EGFR/Ras signalling pathway and cholesterol homeostasis. Int. J. Biochem. Cell Biol., 2010, 42(5), 580-584.
55. Hoshi, N.; Langeberg, L.K.; Gould, C.M.; Newton, A.C.; Scott, J.D. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol. Cell, 2010, 37(4), 541-550.
56. Inagaki, K.; Chen, L.; Ikeno, F.; Lee, F.H.; Imahashi, K.; Bouley, D.M.; Rezaee, M.; Yock, P.G.; Murphy, E.; Mochly-Rosen, D. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation, 2003, 108(19), 2304-2307.
57. Kheifets, V.; Bright, R.; Inagaki, K.; Schechtman, D.; Mochly-Rosen, D. Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function. J. Biol. Chem., 2006, 281(32), 23218-23226.
58. Schmitz-Peiffer, C.; Browne, C.L.; Walker, J.H.; Biden, T.J. Activated protein kinase C alpha associates with annexin VI from skeletal muscle. Biochem. J., 1998, 330(Pt 2), 675-681.
59. Kirschner, L.S.; Yin, Z.; Jones, G.N.; Mahoney, E. Mouse models of altered protein kinase A signaling. Endocr. Relat. Cancer, 2009, 16(3), 773-793.
60. Towns, R.; Menon, K.M. The role of cyclic AMP response element binding protein in transactivation of scavenger receptor class B type I promoter in transfected cells and in primary cultures of rat theca-interstitial cells. Mol. Cell Endocrinol., 2005, 245(1-2), 23-30.
61. Murao, K.; Imachi, H.; Yu, X.; Cao, W.M.; Muraoka, T.; Dobashi, H.; Hosomi, N.; Haba, R.; Iwama, H.; Ishida, T. The transcriptional factor prolactin regulatory element-binding protein mediates the gene transcription of adrenal scavenger receptor class B type I via 3',5'-cyclic adenosine 5'-monophosphate. Endocrinology, 2008, 149(12), 6103-6112.
62. Gevry, N.Y.; Lalli, E.; Sassone-Corsi, P.; Murphy, B.D. Regulation of niemann-pick c1 gene expression by the 3'5'-cyclic adenosine monophosphate pathway in steroidogenic cells. Mol. Endocrinol., 2003, 17(4), 704-715.
63. Manson, M.E.; Corey, D.A.; White, N.M.; Kelley, T.J. cAMPmediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 295(5), L809-819.
64. Nakamura, T.; Shibata, N.; Nishimoto-Shibata, T.; Feng, D.; Ikemoto, M.; Motojima, K.; Iso, O.N.; Tsukamoto, K.; Tsujimoto, M.; Arai, H. Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1. Proc. Natl. Acad Sci. USA., 2005, 102(38), 13404-13409.
65. Kocher, O.; Yesilaltay, A.; Cirovic, C.; Pal, R.; Rigotti, A.; Krieger, M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem., 2003, 278(52), 52820-52825.
66. Kocher, O.; Krieger, M. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr. Opin. Lipidol., 2009, 20(3), 236-241.
67. Bernard, D.W.; Rodriguez, A.; Rothblat, G.H.; Glick, J.M. cAMP stimulates cholesteryl ester clearance to high density lipoproteins in J7774 macrophages. J. Biol. Chem., 1991, 266(2), 710-716.
68. Bortnick, A.E.; Rothblat, G.H.; Stoudt, G.; Hoppe, K.L.; Royer, L.J.; McNeish, J.; Francone, O.L. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J. Biol. Chem., 2000, 275(37), 28634-28640.
69. Oram, J.F.; Lawn, R.M.; Garvin, M.R.; Wade, D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem., 2000, 275(44), 34508-34511.
70. Zheng, P.; Horwitz, A.; Waelde, C.A.; Smith, J.D. Stably transfected ABCA1 antisense cell line has decreased ABCA1 mRNA and cAMP-induced cholesterol efflux to apolipoprotein AI and HDL. Biochim. Biophys. Acta, 2001, 1534(2-3), 121-128.
71. Kritharides, L.; Christian, A.; Stoudt, G.; Morel, D.; Rothblat, G.H. Cholesterol metabolism and efflux in human THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol., 1998, 18(10), 1589-1599.
72. Contreras, J.A.; Lasuncion, M.A. Essential differences in cholesteryl ester metabolism between human monocyte-derived and J774 macrophages. Evidence against the presence of hormonesensitive lipase in human macrophages. Arterioscler. Thromb. Vasc. Biol., 1994, 14(3), 443-452.
73. Sakr, S.W.; Williams, D.L.; Stoudt, G.W.; Phillips, M.C.; Rothblat, G.H. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim. Biophys. Acta, 1999, 1438(1), 85-98.
74. Smith, J.D.; Miyata, M.; Ginsberg, M.; Grigaux, C.; Shmookler, E.; Plump, A.S. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J. Biol. Chem., 1996, 271(48), 30647-30655.
75. Cavelier, L.B.; Qiu, Y.; Bielicki, J.K.; Afzal, V.; Cheng, J.F.; Rubin, E.M. Regulation and activity of the human ABCA1 gene in transgenic mice. J. Biol. Chem., 2001, 276(21), 18046-18051.
76. Haidar, B.; Denis, M.; Marcil, M.; Krimbou, L.; Genest, J. Jr. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J. Biol. Chem., 2004, 279(11), 9963-9969.
77. Lin, G.; Bornfeldt, K.E. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem. Biophys. Res. Commun., 2002, 290(2), 663-669.
78. Hu, Y.W.; Ma, X.; Li, X.X.; Liu, X.H.; Xiao, J.; Mo, Z.C.; Xiang, J.; Liao, D.F.; Tang, C.K. Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis, 2009, 204(2), e35-43.
79. Taylor, S.S.; Kim, C.; Cheng, C.Y.; Brown, S.H.; Wu, J.; Kannan, N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim. Biophys. Acta, 2008, 1784(1), 16-26.
80. Hirano, K.; Matsuura, F.; Tsukamoto, K.; Zhang, Z.; Matsuyama, A.; Takaishi, K.; Komuro, R.; Suehiro, T.; Yamashita, S.; Takai, Y.; Matsuzawa, Y. Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease-the small G protein may play a role in cholesterol efflux. FEBS Lett., 2000, 484(3), 275-279.
81. Tsukamoto, K.; Hirano, K.; Tsujii, K.; Ikegami, C.; Zhongyan, Z.; Nishida, Y.; Ohama, T.; Matsuura, F.; Yamashita, S.; Matsuzawa, Y. ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem. Biophys. Res. Commun., 2001, 287(3), 757-765.
82. Nofer, J.R.; Feuerborn, R.; Levkau, B.; Sokoll, A.; Seedorf, U.; Assmann, G. Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J. Biol. Chem., 2003, 278(52), 53055-53062.
83. Nofer, J.R.; Remaley, A.T.; Feuerborn, R.; Wolinnska, I.; Engel, T.; von Eckardstein, A.; Assmann, G. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J. Lipid Res., 2006, 47(4), 794-803.
84. Tsukamoto, K.; Hirano, K.; Yamashita, S.; Sakai, N.; Ikegami, C.; Zhang, Z.; Matsuura, F.; Hiraoka, H.; Matsuyama, A.; Ishigami, M.; Matsuzawa, Y. Retarded intracellular lipid transport associated with reduced expression of Cdc42, a member of Rho-GTPases, in human aged skin fibroblasts: a possible function of Cdc42 in mediating intracellular lipid transport. Arterioscler. Thromb. Vasc. Biol., 2002, 22(11), 1899-1904.
85. Neufeld, E.B.; Remaley, A.T.; Demosky, S.J.; Stonik, J.A.; Cooney, A.M.; Comly, M.; Dwyer, N.K.; Zhang, M.; Blanchette-Mackie, J.; Santamarina-Fojo, S.; Brewer, H.B. Jr. Cellular localization and trafficking of the human ABCA1 transporter. J. Biol. Chem., 2001, 276(29), 27584-27590.
86. Neufeld, E.B.; Stonik, J.A.; Demosky, S.J., Jr.; Knapper, C.L.; Combs, C.A.; Cooney, A.; Comly, M.; Dwyer, N.; Blanchette-Mackie, J.; Remaley, A.T.; Santamarina-Fojo, S.; Brewer, H.B. Jr. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem., 2004, 279(15), 15571-15578.
87. Stamnes, M. Regulating the actin cytoskeleton during vesicular transport. Curr. Opin. Cell Biol., 2002, 14(4), 428-433.
88. Okuhira, K.; Fitzgerald, M.L.; Tamehiro, N.; Ohoka, N.; Suzuki, K.; Sawada, J.; Naito, M.; Nishimaki-Mogami, T. Binding of PDZRhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J. Biol. Chem., 2010, 285(21), 16369-16377.
89. Okuhira, K.; Fitzgerald, M.L.; Sarracino, D.A.; Manning, J.J.; Bell, S.A.; Goss, J.L.; Freeman, M.W. Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta1-syntrophin in cholesterol efflux. J. Biol. Chem., 2005, 280(47), 39653-39664.
90. Lu, R.; Arakawa, R.; Ito-Osumi, C.; Iwamoto, N.; Yokoyama, S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler. Thromb. Vasc. Biol., 2008, 28(10), 1820-1824.
91. Qin, Q.; Liao, G.; Baudry, M.; Bi, X. Cholesterol Perturbation in Mice Results in p53 Degradation and Axonal Pathology through p38 MAPK and Mdm2 Activation. PLoS One, 2010, 5(4), e9999.
92. Zhou, Q.; Liao, J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des., 2009, 15(5), 467-478.
93. Shirai, H.; Autieri, M.; Eguchi, S. Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr. Opin. Nephrol. Hypertens., 2007, 16(2), 111-115.
94. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14(1), 37-44.
95. Lahera, V.; Goicoechea, M.; de Vinuesa, S.G.; Miana, M.; de las Heras, N.; Cachofeiro, V.; Luno, J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem., 2007, 14(2), 243-248.
96. Bishop, A.L.; Hall, A. Rho GTPases and their effector proteins. Biochem., J., 2000, 348(Pt 2), 241-255.
97. Deacon, S.W.; Peterson, J.R. Chemical inhibition through conformational stabilization of Rho GTPase effectors. Handb. Exp. Pharmacol., 2008, 186(IV), 431-460.
98. Marchioni, F.; Zheng, Y. Targeting rho GTPases by peptidic structures. Curr. Pharm. Des., 2009, 15(21), 2481-2487.
99. Shutes, A.; Onesto, C.; Picard, V.; Leblond, B.; Schweighoffer, F.; Der, C.J. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem., 2007, 282(49), 35666-35678.
100. Klappe, K.; Hummel, I.; Hoekstra, D.; Kok, J.W. Lipid dependence of ABC transporter localization and function. Chem. Phys. Lipids, 2009, 161(2), 57-64.
101. Fitzgerald, M.L.; Mujawar, Z.; Tamehiro, N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis, 2010, 211(2), 361-370.
102. Tang, C.; Vaughan, A.M.; Oram, J.F. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biol. Chem., 2004, 279(9), 7622-7628.
103. Tang, C.; Vaughan, A.M.; Anantharamaiah, G.M.; Oram, J.F. Janus kinase 2 modulates the lipid-removing but not proteinstabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res., 2006, 47(1), 107-114.
104. Vaughan, A.M.; Tang, C.; Oram, J.F. ABCA1 mutants reveal an interdependency between lipid export function, apoA-I binding activity, and Janus kinase 2 activation. J. Lipid Res., 2009, 50(2), 285-292.
105. Karwatsky, J.; Ma, L.; Dong, F.; Zha, X. Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+-dependent calcineurin signaling. J. Lipid Res., 2010, 51(5), 1144-1156.
106. Shao, B.; Pennathur, S.; Pagani, I.; Oda, M.N.; Witztum, J.L.; Oram, J.F.; Heinecke, J.W. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem., 2010, 285(24), 18473-18484.
107. Iwamoto, N.; Lu, R.; Tanaka, N.; Abe-Dohmae, S.; Yokoyama, S. Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates highdensity lipoprotein generation. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1446-1452.
108. Ishii, N.; Matsumura, T.; Kinoshita, H.; Fukuda, K.; Motoshima, H.; Senokuchi, T.; Nakao, S.; Tsutsumi, A.; Kim-Mitsuyama, S.; Kawada, T.; Takeya, M.; Miyamura, N.; Nishikawa, T.; Araki, E. Nifedipine Induces Peroxisome Proliferator-Activated Receptorgamma Activation in Macrophages and Suppresses the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Biol., 2010, 30(8), 1598-1605.
109. Fu, Y.; Hoang, A.; Escher, G.; Parton, R.G.; Krozowski, Z.; Sviridov, D. Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J. Biol. Chem., 2004, 279(14), 14140-14146.
110. Agassandian, M.; Miakotina, O.L.; Andrews, M.; Mathur, S.N.; Mallampalli, R.K. Pseudomonas aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha-RXR. Biochem. J., 2007, 403(3), 409-420.
111. Zhou, X.; Yin, Z.; Guo, X.; Hajjar, D.P.; Han, J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J. Biol. Chem., 2010, 285(9), 6316-6326.
112. Chinetti, G.; Fruchart, J.C.; Staels, B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR. Biochem. Soc. Trans., 2006, 34(Pt 6), 1128-1131.
113. Zelcer, N.; Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest., 2006, 116(3), 607-614.
114. Burns, K.A.; Vanden Heuvel, J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta, 2007, 1771(8), 952-960.
115. Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr. Opin. Cell Biol., 2005, 17(2), 216-222.
116. Chen, M.; Bradley, M.N.; Beaven, S.W.; Tontonoz, P. Phosphorylation of the liver X receptors. FEBS Lett., 2006, 580(20), 4835-4841.
117. Han, J.; Hajjar, D.P.; Zhou, X.; Gotto, A.M. Jr.; Nicholson, A.C. Regulation of peroxisome proliferator-activated receptor-gammamediated gene expression. A new mechanism of action for high density lipoprotein. J. Biol. Chem., 2002, 277(26), 23582-23586.
118. George, J.; Afek, A.; Keren, P.; Herz, I.; Goldberg, I.; Haklai, R.; Kloog, Y.; Keren, G. Functional inhibition of Ras by S-trans, transfarnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation, 2002, 105(20), 2416-2422.
119. Sugita, M.; Sugita, H.; Kaneki, M. Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc., Biol., 2007, 27(6), 1390-1395.
120. Miura, S.; Matsuo, Y.; Saku, K. Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling. Atherosclerosis, 2004, 175(2), 235-243.
121. Engel, T.; Lueken, A.; Bode, G.; Hobohm, U.; Lorkowski, S.; Schlueter, B.; Rust, S.; Cullen, P.; Pech, M.; Assmann, G.; Seedorf, U. ADP-ribosylation factor (ARF)-like 7 (ARL7) is induced by cholesterol loading and participates in apolipoprotein AI-dependent cholesterol export. FEBS Lett., 2004, 566(1-3), 241-246.
122. Linder, M.D.; Mayranpaa, M.I.; Peranen, J.; Pietila, T.E.; Pietiainen, V.M.; Uronen, R.L.; Olkkonen, V.M.; Kovanen, P.T.; Ikonen, E. Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol efflux in primary human macrophages. Arterioscler. Thromb. Vasc. Biol., 2009, 29(6), 883-888.
123. McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Chappell, W.H.; Russo, S.; Ove, R.; Milella, M.; Tafuri, A.; Lunghi, P.; Bonati, A.; Stivala, F.; Nicoletti, F.; Libra, M.; Martelli, A.M.; Montalto, G.; Cervello, M. Emerging MEK inhibitors. Expert. Opin. Emerg. Drugs, 2010, 15(2), 203-223.
124. Sebolt-Leopold, J.S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Des., 2004, 10(16), 1907-1914.
125. Mardones, P.; Pilon, A.; Bouly, M.; Duran, D.; Nishimoto, T.; Arai, H.; Kozarsky, K.F.; Altayo, M.; Miquel, J.F.; Luc, G.; Clavey, V.; Staels, B.; Rigotti, A. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J. Biol. Chem., 2003, 278(10), 7884-7890.
126. Lan, D.; Silver, D.L. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J. Biol. Chem., 2005, 280(24), 23390-23396.
127. Wang, P.Y.; Weng, J.; Lee, S.; Anderson, R.G. The N terminus controls sterol binding while the C terminus regulates the scaffolding function of OSBP. J. Biol. Chem., 2008, 283(12), 8034-8045.
128. Wang, P.Y.; Liu, P.; Weng, J.; Sontag, E.; Anderson, R.G. A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity. EMBO J., 2003, 22(11), 2658-2667.
129. Olkkonen, V.M.; Levine, T.P. Oxysterol binding proteins: in more than one place at one time? Biochem. Cell Biol., 2004, 82(1), 87-98.
130. Bowden, K.; Ridgway, N.D. OSBP negatively regulates ABCA1 protein stability. J. Biol. Chem., 2008, 283(26), 18210-18217.
131. Ramet, M.E.; Ramet, M.; Lu, Q.; Nickerson, M.; Savolainen, M.J.; Malzone, A.; Karas, R.H. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol., 2003, 41(12), 2288-2297.
132. Assanasen, C.; Mineo, C.; Seetharam, D.; Yuhanna, I.S.; Marcel, Y.L.; Connelly, M.A.; Williams, D.L.; de la Llera-Moya, M.; Shaul, P.W.; Silver, D.L. Cholesterol binding, efflux, and a PDZinteracting domain of scavenger receptor-BI mediate HDL-initiated signaling. J. Clin. Invest., 2005, 115(4), 969-977.
133. Argraves, K.M.; Argraves, W.S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res., 2007, 48(11), 2325-2333.
134. Nofer, J.R.; van der Giet, M.; Tolle, M.; Wolinska, I.; von Wnuck Lipinski, K.; Baba, H.A.; Tietge, U.J.; Godecke, A.; Ishii, I.; Kleuser, B.; Schafers, M.; Fobker, M.; Zidek, W.; Assmann, G.; Chun, J.; Levkau, B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004, 113(4), 569-581.
135. Okajima, F.; Sato, K.; Kimura, T. Anti-atherogenic actions of highdensity lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr. J., 2009, 56(3), 317-334.
136. Blom, T.; Back, N.; Mutka, A.L.; Bittman, R.; Li, Z.; de Lera, A.; Kovanen, P.T.; Diczfalusy, U.; Ikonen, E. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ. Res., 2010, 106(4), 720-729.
137. Babitt, J.; Trigatti, B.; Rigotti, A.; Smart, E.J.; Anderson, R.G.; Xu, S.; Krieger, M. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J. Biol. Chem., 1997, 272(20), 13242-13249.
138. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol., 2000, 1(1), 31-39.
139. Ikonen, E.; Parton, R.G. Caveolins and cellular cholesterol balance. Traffic, 2000, 1(3), 212-217.
140. Wang, X.Q.; Yan, Q.; Sun, P.; Liu, J.W.; Go, L.; McDaniel, S.M.; Paller, A.S. Suppression of epidermal growth factor receptor signaling by protein kinase C-alpha activation requires CD82, caveolin-1, and ganglioside. Cancer Res., 2007, 67(20), 9986-9995.
141. Chadda, R.; Howes, M.T.; Plowman, S.J.; Hancock, J.F.; Parton, R.G.; Mayor, S. Cholesterol-sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway. Traffic, 2007, 8(6), 702-717.
142. Roy, S.; Luetterforst, R.; Harding, A.; Apolloni, A.; Etheridge, M.; Stang, E.; Rolls, B.; Hancock, J.F.; Parton, R.G. Dominantnegative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol., 1999, 1(2), 98-105.
143. Grimmer, S.; van Deurs, B.; Sandvig, K. Membrane ruffling and macropinocytosis in A431 cells require cholesterol. J. Cell Sci., 2002, 115(Pt 14), 2953-2962.
144. del Pozo, M.A.; Alderson, N.B.; Kiosses, W.B.; Chiang, H.H.; Anderson, R.G.; Schwartz, M.A. Integrins regulate Rac targeting by internalization of membrane domains. Science, 2004, 303(5659), 839-842.
145. Furuchi, T.; Anderson, R.G. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem., 1998, 273(33), 21099-21104.
146. Corey, D.A.; Kelley, T.J. Elevated small GTPase activation influences the cell proliferation signaling control in Niemann-Pick type C fibroblasts. Biochim. Biophys. Acta, 2007, 1772(7), 748-754.
147. Sawamura, N.; Gong, J.S.; Garver, W.S.; Heidenreich, R.A.; Ninomiya, H.; Ohno, K.; Yanagisawa, K.; Michikawa, M. Sitespecific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J. Biol. Chem., 2001, 276(13), 10314-10319.
148. Cubells, L.; Vila de Muga, S.; Tebar, F.; Wood, P.; Evans, R.; Ingelmo-Torres, M.; Calvo, M.; Gaus, K.; Pol, A.; Grewal, T.; Enrich, C. Annexin A6-induced alterations in cholesterol transport and caveolin export from the Golgi complex. Traffic, 2007, 8(11), 1568-1589.
149. Pol, A.; Luetterforst, R.; Lindsay, M.; Heino, S.; Ikonen, E.; Parton, R.G. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J. Cell Biol., 2001, 152(5), 1057-1070.
150. Zhang, Y.; Ahmed, A.M.; McFarlane, N.; Capone, C.; Boreham, D.R.; Truant, R.; Igdoura, S.A.; Trigatti, B.L. Regulation of SR-BImediated selective lipid uptake in Chinese hamster ovary-derived cells by protein kinase signaling pathways. J. Lipid Res., 2007, 48(2), 405-416.